manalikamdar
@mana1981
Followers
739
Following
3K
Media
47
Statuses
714
HematoOncologist, eternal optimist, passionate about making every moment count
Denver, CO
Joined October 2009
A huge thanks to @mana1981, of @CUAnschutz, for stopping by during #ASH25 to discuss long-term follow-up data from the TRANSFORM study of liso-cel in R/R LBCL! Check out our site for more #lymsm insights from the meeting! @ASH_hematology #hematology
https://t.co/d1zYo7xtsq
0
2
6
Continue Day 2 at #ASH25 by catching Dr. Manali Kamdar’s (@mana1981) presentation on 4-year long-term follow-up from the TRANSFORM study. Share your patient stories of CD19 #CART cell therapy for r/r #LBCL. https://t.co/OQ3adayMTw
0
2
3
Our @CULymphoma faculty Dr. @majorajay was just featured @CUCancerCenter regarding his recent analysis published @JNCI_Now regarding risk factors and mortality related to subsequent colorectal cancer in childhood cancer survivors. #onctwitter
https://t.co/JnLwMacr3J
news.cuanschutz.edu
Ajay Major's research found childhood cancer survivors got subsequent colorectal cancer at younger ages and had high colorectal cancer mortality rates.
0
2
6
Our lead Dr. @mana1981 is senior author of a study in @ASTCT showing 95-97% of CRS/ICANS events occur before day 15 after liso-cel infusion in the real-world setting. These results led to the recent FDA REMS changes for post-CAR monitoring. #lymsm #tcellrx
https://t.co/zj0tyIqvZe
0
6
14
CRS/ICANS onset after liso-cel - 702 trial pts: 98%/88% before D+15 - 877 RW pts: 97%/95% before D+15 - no G3+ CRS/ICANS after D+15 in trial pts, only 2 G3-4 events in RW population This led to change in REMS to only 2 weeks of monitoring after CAR. #lymsm
https://t.co/B8OQhpjl8m
0
3
7
Congratulations to Dr. @majorajay @CUHematology on presentation of his group's study at @WorldSIOP. Dr. Major is the Chair of the @glow_nlphl Patient-Reported Outcomes Committee, which focuses on studying quality of life in NLPHL as a rare disease: https://t.co/FaHPuCsGcP
#lymsm
glowconsortium.org
GLOW is an interdisciplinary research network of NLPHL experts, advocates, and cancer support professionals from over 25 countries.
Dr. @drvcrabtree @StJude presented the findings of our @glow_nlphl qualitative study of patient and care partner perspectives in NLPHL at @WorldSIOP #SIOPCongress. Read the study by @majorajay et al.: https://t.co/ojfmHcYaK4
#lymsm #NLPHLsm
1
2
5
Dr. @majorajay @CUHematology contributed (with @JessicaAllenMD) to a large multicenter study of real-world outcomes of polatuzumab in frontline and relapsed/refractory DLBCL, now published @CCR_AACR. #lymsm
https://t.co/mXeNONq0U9
0
4
12
Our @CULymphoma lead Dr. @mana1981 just published a consensus piece on expanded eligibility for CAR T-cell therapy (which is not the same as transplant eligibility!) #lymsm #tcellrx cc @CUAnschutz @CUCancerCenter
https://t.co/78DlmWHOX5
0
2
10
We just published our paper comparing eligibility criteria for #CAR-T vs autoSCT. They are NOT the same! Key message: Most patients are eligible for CAR-T, even with significant comorbidities. Collaboration with other specialists is key to optimizing patients clinical situation.
2
19
57
▶️Really important analysis of #pirtobrutinib resistance in R/R #CLL from BRUIN now online in @BloodPortfolio Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia https://t.co/m1UmmVDFr0
ashpublications.org
Key Points. The most common acquired BTK mutations detected at PD during pirtobrutinib treatment were T474X and L528W.One-third of patients did not acquire
0
7
27
We're so pleased to welcome Manali Kamdar (@mana1981) to our Lymphoma Editorial Board on VJHemOnc! Check our Dr Kamdar's interviews and lymphoma insights below: 👉 https://t.co/vlschFaaGw
#LymSM #HemOnc
0
1
4
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. @JCO_ASCO
ascopubs.org
We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line primary refractory/early relapsed (≤12 months) large...
0
9
35
Post–CAR T-Cell Monitoring Optimization Improves Access and Safety for Patients With B-Cell Malignancies @mana1981 @CUCancerCenter #lymsm #leusm #hematology
https://t.co/WvmGwtsPf1
onclive.com
Manali Kamdar, MD, discusses advances with CAR T-cell therapy in B-cell malignancies and the monitoring needs for CRS and ICANS that affect patient access.
0
3
5
#BloodCancerAwarenessMonth: The latest study from CU Cancer Center member Manali Kamdar (@mana1981), MD, focuses on CD19 CAR T-cell therapies for lymphoma, and contributes to an FDA regulatory change that she says could broaden access ⬇️ https://t.co/MmNGmR9NhX
news.cuanschutz.edu
Research led by a CU Cancer Center member has contributed to a regulatory change that could broaden access to a form of CAR T-cell therapy for lymphoma.
1
2
9
Welcome to our new @CUHematology faculty Dr. Cassandra Duarte! Dr. Duarte is joining our @CULymphoma program with specialization in aggressive B-cell lymphomas as well as mastocytosis and histiocytic disorders. #lymsm
0
3
14
Childhood cancer survivors face higher mortality after colorectal secondary cancers, with 50% diagnosed before age 40. Our new @JNCI_Now manuscript highlights need for tailored screening guidelines. #onctwitter #survonc
https://t.co/iBPTXUPPoP
1
3
14
“It’s a huge win for patients": Research led by @CUCancerCenter member @mana1981, MD, has contributed to a change that could broaden access to a form of CAR T-cell therapy for lymphoma. My latest story for @CUMedicalSchool at @CUAnschutz. #cucityofhealth
https://t.co/tBa5B4POi0
news.cuanschutz.edu
Research led by a CU Cancer Center member has contributed to a regulatory change that could broaden access to a form of CAR T-cell therapy for lymphoma.
0
5
17
#Hematology Outcomes of bispecific antibody therapy after #CARTcell failure in relapsed/refractory large B-cell #lymphoma #DLBCL | Blood Advances | American Society of Hematology #lymsm
ashpublications.org
Key PointsEarly relapse after CAR-T (≤3 months) is associated with poor outcome of subsequent BsAb therapy.Lactate dehydrogenase, higher International Prog
0
10
36